Iranian Red Crescent Medical Journal

Published by: Kowsar

Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety

Farhad Assarzadegan 1 , Hanif Tabesh 2 , * , Seyed-Mostafa Hosseini-Zijoud 3 , Andrew David Beale 4 , Arya Shoghli 2 , Mahmood Ghafoori Yazdi 2 , Behnam Mansouri 1 , Omid Hesami 1 , Nahid Beladi Moghadam 1 and Hosein Delavar Kasmaei 5
Authors Information
1 Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
4 Research Complex at Harwell, London, United Kingdom
5 Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: September 01, 2016, 18 (9); e23768
  • Published Online: April 30, 2016
  • Article Type: Research Article
  • Received: September 22, 2014
  • Revised: November 24, 2014
  • Accepted: December 20, 2014
  • DOI: 10.5812/ircmj.23768

To Cite: Assarzadegan F, Tabesh H, Hosseini-Zijoud S, Beale A D, Shoghli A, et al. Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety, Iran Red Crescent Med J. 2016 ; 18(9):e23768. doi: 10.5812/ircmj.23768.

Abstract
Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Kabbouche MA, Gilman DK. Management of migraine in adolescents. Neuropsychiatr Dis Treat. 2008; 4(3): 535-48[PubMed]
  • 2. Walter G, Bradley. , Robert B, Daroff. , Gerald M, Fenichel. , et al. Neurology in Clinical Practice. 2008;
  • 3. Prensky A. Childhood Migraine Headache Syndromes. Curr Treat Options Neurol. 2001; 3(3): 257-70[PubMed]
  • 4. Sonal Sekhar M, Sasidharan S, Joseph S, Kumar A. Migraine management: How do the adult and paediatric migraines differ? Saudi Pharm J. 2012; 20(1): 1-7[DOI][PubMed]
  • 5. Walter G, Bradley. , Robert B, Daroff. , Gerald M, Fenichel J, et al. Neurology in Clinical Practice. 2008;
  • 6. Bermejo PE, Dorado R. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol. 2009; 32(2): 103-6[DOI][PubMed]
  • 7. Cuvellier JC, Riquet A, Vallee L. [Antiepileptic drugs in pediatric migraine]. Arch Pediatr. 2008; 15(11): 1693-9[DOI][PubMed]
  • 8. Drake MJ, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin Neuropharmacol. 2004; 27(6): 278-80[PubMed]
  • 9. Ertas M, Baykan B, Orhan EK, Zarifoglu M, Karli N, Saip S, et al. One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults. J Headache Pain. 2012; 13(2): 147-57[DOI][PubMed]
  • 10. Stewart WF, Roy J, Lipton RB. Migraine prevalence, socioeconomic status, and social causation. Neurology. 2013; 81(11): 948-55[DOI][PubMed]
  • 11. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010; 30(9): 1065-72[DOI][PubMed]
  • 12. Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia. 2006; 26(10): 1199-202[DOI][PubMed]
  • 13. Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache. 2006; 46(5): 804-7[DOI][PubMed]
  • 14. Hoffmann J, Akerman S, Goadsby PJ. Efficacy and mechanism of anticonvulsant drugs in migraine. Expert Rev Clin Pharmacol. 2014; 7(2): 191-201[DOI][PubMed]
  • 15. Jeavons PM, Clark JE. Sodium valproate in treatment of epilepsy. Br Med J. 1974; 2(5919): 584-6[PubMed]
  • 16. Zonisamide. 2014;
  • 17. Cavanna AE, Seri S. Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities. Epilepsy Behav. 2013; 29(2): 281-4[DOI][PubMed]
  • 18. Dupont S, Biraben A, Lavernhe G, Marquet T, Allaf B. Management and monitoring of patients treated with zonisamide: the OZONE study. Epileptic Disord. 2013; 15(3): 278-88[DOI][PubMed]
  • 19. Sato S, Nishinaka K, Takahashi S, Hirobe M, Tsukamoto T. [Bilateral urolithiasis with zonisamide developed for a short period of time in a 10-year-old girl with intractable epilepsy]. Nihon Hinyokika Gakkai Zasshi. 2013; 104(5): 674-7[PubMed]
  • 20. Fujita Y, Hasegawa M, Nabeshima K, Tomita M, Murakami K, Nakai S, et al. Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome. Intern Med. 2010; 49(5): 409-13[PubMed]
  • 21. Ijiri Y, Inoue T, Fukuda F, Suzuki K, Kobayashi T, Shibahara N, et al. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Epilepsia. 2004; 45(8): 924-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments